SpectRx cervical cancer detection
This article was originally published in The Gray Sheet
Executive Summary
Grant of $690,000 from the National Cancer Institute, announced Sept. 13, will go toward completing a pivotal trial for SpectRx' noninvasive LightTouch cervical cancer detection technology. More than 1,100 women have been enrolled in the five-site trial, expected to complete enrollment in 2007. The firm will seek expedited PMA approval of LightTouch as a triage step for women with positive Pap or HPV tests to confirm whether colposcopy and biopsy are warranted. SpectRx has received a total of $3.2 mil. in NCI funding for the product...
You may also be interested in...
SpectRx seeks buyer for insulin pump infusion set unit
Firm's SimpleChoice insulin pump infusion set business is up for sale as part of a broader SpectRx reorganization aimed at refocusing the company on its noninvasive LightTouch cervical cancer detection technology, including funding ongoing pivotal trials of the device, the firm says March 15. SpectRx also is seeking a partner for its development-stage continuous glucose monitoring technology. LightTouch, which uses light to scan the cervix for disease, is intended as a triage step for women with positive Pap smear or human papillomavirus (HPV) tests to confirm whether colposcopy and biopsy are warranted (1"The Gray Sheet" Sept. 18, 2006, In Brief)...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.